Immunogenicity % safety study of a booster dose of GSK Biologicals’ meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in primed healthy toddlers.
Meningococcal Serogroups A, C, W-135 and Y-Tetanus Toxoid Conjugate Vaccine
Infections, Meningococcal
Phase 3
A booster study 110871 was conducted. The results of this study 110870 are summarized with 110871 on the GSK Clinical Study Register.
June 2015